Galimedix, Inc. | WebDisclosure

Basculer en Français

10456	Companies
219568	Keywords
148951	Articles
116101	Press releases

Home
Companies
Galimedix, Inc.

PRESS RELEASE

published on 05/06/2025 at 14:00, 1 year ago

Galimedix Therapeutics completes single ascending dose part of Phase 1 study with oral small molecule, GAL-101, an amyloid beta aggregation modulator
Galimedix Therapeutics completes single ascending dose of Phase 1 study with oral small molecule GAL-101 targeting amyloid beta aggregation modulator, supporting oral administration route. Next study arms and indications revealed

Galimedix Therapeutics GAL-101 Oral Administration Phase 1 Study Amyloid Beta
BRIEF

published on 04/01/2025 at 09:05, 1 year 1 month ago

Galimedix Reports Promising Data for Alzheimer's Treatment

Alzheimer's Disease GAL-201 Galimedix Therapeutics Neuroinflammation Amyloid-β Aggregation
BRIEF

published on 04/01/2025 at 09:05, 1 year 1 month ago

Galimedix publie des données prometteuses pour le traitement de la maladie d'Alzheimer

GAL-201 Maladie D'Alzheimer Galimedix Therapeutics Neuroinflammation Agrégation De L'amyloïde-β
PRESS RELEASE

published on 04/01/2025 at 09:00, 1 year 1 month ago

Galimedix Therapeutics presents further scientific data showing disease-modifying potential of oral GAL-201 in Alzheimer’s disease as well as beneficial effects on synaptic function and neuroimmunomod
Galimedix Therapeutics presents new preclinical data on GAL-201 at AD/PD 2025, showing promise in Alzheimer’s disease treatment by targeting misfolded Aβ monomers and reducing Aβ plaques with anti-inflammatory effects

Alzheimer's Disease Preclinical Data GAL-201 Galimedix Therapeutics Neuroinflammation
BRIEF

published on 03/24/2025 at 15:12, 1 year 2 months ago

Galimedix Therapeutics présente un traitement préclinique prometteur contre la maladie d'Alzheimer

Galimedix Therapeutics Neuroprotection Données Précliniques Traitement De La Maladie D'Alzheimer Bêta-amyloïde
BRIEF

published on 03/24/2025 at 15:12, 1 year 2 months ago

Galimedix Therapeutics to Present Promising Preclinical Alzheimer’s Treatment

Preclinical Data Galimedix Therapeutics Neuroprotection Alzheimer's Treatment Amyloid-beta
PRESS RELEASE

published on 03/24/2025 at 15:07, 1 year 2 months ago

Galimedix Therapeutics to present positive pre-clinical data with amyloid beta aggregation modulator in development for oral Alzheimer’s disease treatment at AD/PD™ 2025 Conference
Galimedix Therapeutics to present positive pre-clinical data with amyloid beta aggregation modulator for oral Alzheimer's disease treatment at AD/PD(TM) 2025 Conference

Alzheimer's Disease Galimedix Therapeutics Pre-clinical Data AD/PD 2025 Conference Aβ Aggregation Modulator
BRIEF

published on 12/23/2024 at 17:35, 1 year 5 months ago

Galimedix débute un essai de phase 2 avec les gouttes ophtalmiques GAL-101 pour la DMLA sèche

Étude De Phase 2 Neuroprotection GAL-101 DMLA Sèche Atrophie Géographique
BRIEF

published on 12/23/2024 at 17:35, 1 year 5 months ago

Galimedix Begins Phase 2 Trial with GAL-101 Eye Drops for Dry AMD

Phase 2 Study Neuroprotection GAL-101 Dry AMD Geographic Atrophy
PRESS RELEASE

published on 12/23/2024 at 17:30, 1 year 5 months ago

Galimedix Therapeutics initiates pivotal Phase 2 study with GAL-101 eye drops in dry AMD
Galimedix Therapeutics initiates Phase 2 study with GAL-101 eye drops for dry AMD, aiming to slow geographic atrophy growth. Trial led by world-leading retina experts and funded by Théa Open Innovation

Galimedix Therapeutics Phase 2 Study GAL-101 Dry AMD Geographic Atrophy

Accesswire

Published on 05/26/2026 at 14:30, 24 minutes ago

Klondike Gold Announces 2026 Diamond Drilling Program Underway to Update and Expand Gold Mineral Resources
Published on 05/26/2026 at 14:30, 24 minutes ago

Predictiv AI Announces Strategic Healthcare Partnership and CloudRep AI Integration with Clinicmaster Following Successful Multi-Clinic Pilot Deployments
Published on 05/26/2026 at 14:30, 24 minutes ago

In the Ebola Emergency, NV-387 is Ready to be Shipped to DRC, and It Compares Favorably as a Treatment for Ebola Versus Possible Options, Says NanoViricides
Published on 05/26/2026 at 14:15, 39 minutes ago

Worksport (NASDAQ:WKSP) Secures U.S. Patent For 'Industry-First' Zerofrost Heat Pump Through Its Subsidiary, Terravis Energy
Published on 05/26/2026 at 14:00, 54 minutes ago

Ameriwest Critical Metals Provides Q2 2026 Corporate Update and Announces Live CEO Investor Webinar

View all ACCESSWIRE

EQS Group

Published on 05/26/2026 at 14:46, 7 minutes ago

EQS-Adhoc: 2G Energy AG receives major order to supply power generation equipment to data centers in north America: 2026 revenue forecast confirmed at the upper end of the range; significant revenue growth of 20
Published on 05/26/2026 at 14:35, 18 minutes ago

Bitmine Immersion Technologies (BMNR) Announces ETH Holdings Reach 5.39 Million Tokens, and Total Crypto and Total Cash Holdings of $12.3 Billion
Published on 05/26/2026 at 14:15, 39 minutes ago

Siegfried successfully places senior bonds of CHF 200 million
Published on 05/26/2026 at 13:33, 1 hour 20 minutes ago

Changes on the Executive Board of Hapag-Lloyd AG
Published on 05/26/2026 at 13:25, 1 hour 28 minutes ago

Coinsilium Group Limited: Coinsilium Backed Otomato Unveils UK Technology Venture Builder Improbable as its new Strategic Investor

Les Echos

Published on 05/26/2026 at 07:59, 6 hours 55 minutes ago

Saint-Gobain signe un accord de cession de son activité de distribution de carrelage dans les pays nordiques
Published on 05/26/2026 at 07:59, 6 hours 55 minutes ago

Saint-Gobain has signed an agreement for the sale of its Tiles Distribution business in the Nordics
Published on 05/25/2026 at 18:00, 20 hours 54 minutes ago

Déclaration des transactions sur actions propres réalisées du 18/05/2026 au 24/05/2026
Published on 05/25/2026 at 17:45, 21 hours 9 minutes ago

Déclaration hebdomadaire de rachat d'actions
Published on 05/25/2026 at 17:45, 21 hours 9 minutes ago

Weekly share buyback

View all LES ECHOS COMFI WIRE